Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Atritech

2000 FOUNDED
M&A STATUS
21-30 EMPLOYEES
M&A LATEST DEAL TYPE
$712M LATEST DEAL AMOUNT
Description

Developer of minimally invasive technologies designed for the prevention of atrial fibrillation related stroke and related diseases. The company's proprietary product WATCHMAN, offers left atrial appendage system, which is designed to prevent harmful sized blood clots formed in the left atrial appendage from entering into blood streams that causes strokes or other complications thus, enabling on improving the quality of life for patients with atrial fibrillation (AF) by providing a permanent alternative to medications that help reduce the risk of AF related stroke.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Acquirer
Boston Scientific
Primary Office
  • 3750 Annapolis Lane
  • Suite 105
  • Plymouth, MN 55447
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Atritech’s full profile, request a free trial.

Atritech Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 19-Jan-2011 $712M 000.00 00000 Completed Generating Revenue
6. Later Stage VC (Series E) 07-Apr-2009 0000 000.00 00000 Completed Generating Revenue
5. Later Stage VC (Series D) 05-Sep-2007 0000 000.00 00000 Completed Generating Revenue
4. Later Stage VC (Series C) 08-Mar-2006 0000 000.00 000.00 Completed Generating Revenue
3. Convertible Debt 26-Jun-2005 00.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 11-Sep-2003 $10.2M $17.2M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) $7M $7M 000.00 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Atritech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 8,123,560 $0.010000 8% $1.25 $1.25 1x $1.25 8.83%
Series A 5,600,000 $0.010000 8% $1.25 $1.25 1x $1.25 6.09%
To view this company’s complete Cap Table, request access »

Atritech Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Affinity Capital Management Venture Capital Minority 000 0000 000000 0
BioStar Capital Venture Capital Minority 000 0000 000000 0
Cressey & Company PE/Buyout Minority 000 0000 000000 0
Edwards Lifesciences Corporation Minority 000 0000 000000 0
Prism Venture Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »